More than a million people die of Malaria every year, many of them children in Africa. In this context, the results of a Phase III malaria vaccine trial, which was testing the efficacy of the vaccine in preventing clinical and severe malaria in infants aged 6-12 weeks, are highly disappointing.
While vector control and sanitation are the pillars in the battle against malaria, a preventative vaccine could be a valuable tool to fight the disease, particularly in areas where the disease is endemic. Read the complete article in today’s Hindu here
